NCT04444427View on ClinicalTrials.gov

Evaluation of GLR2007 for Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions
Non-small Cell Lung CancerGlioblastoma Multiforme
Interventions
DRUG

GLR2007

Administered orally, once daily for 21 days followed by a 7-day treatment holiday.

Trial Locations (4)

19111

USA001, Philadelphia

47905

USA002, Lafayette

68130

USA005, Omaha

75230

USA004, Dallas

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY